This release was published on August 13, 2026, and reflects information as of that date. Made Scientific's current facilities and capabilities are described on our Facilities page.
This partnership demonstrates a shared vision for building scalable U.S. manufacturing infrastructure to support the growing demand for exosome-based therapeutics and commercial exosome products.
Made Scientific has entered into a binding memorandum of understanding (MOU) with NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) and its U.S. subsidiary, Exo-Top Inc., to serve as NurExone's exclusive U.S. partner for the manufacturing and aseptic fill-finish of its bone marrow-derived exosomes. The partnership will leverage Made Scientific's 60,000-square-foot, FDA and EU GMP Annex 1-compliant facility in Princeton, New Jersey.
Under the agreement, the two companies will begin transferring NurExone's technology while working toward a definitive partnership agreement, with a goal of producing the first GMP-grade exosome batches in the first half of 2027. The proposed deal carries an initial five-year term with options for successive five-year renewals, supporting NurExone's clinical pipeline, as well as its broader commercial exosome ambitions.
"NurExone has developed a differentiated exosome platform with significant clinical and commercial potential. This collaboration combines NurExone's innovative bone marrow-derived exosome platform with Made Scientific's manufacturing and regulatory expertise, creating an integrated pathway to bring exosome-based therapies from development through commercial supply."
- Syed T. Husain, Chairman and CEO of Made Scientific
Read the full press release here.
